| Symbol
| IL1RL1
| contributors: mct - updated : 24-02-2017
|
| HGNC name
| interleukin 1 receptor-like 1
|
| HGNC id
| 5998
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --over
|
|
in sera of SS (Sjogren Syndrome) patients and (Systemic Lupus Erythematosus) patients  | | constitutional
|
|
| --over
|
| |
in patients with greater infarct transmurality and endocardial extent, and in the presence of microvascular obstruction | | constitutional
|
|
| --over
|
| |
elevated concentrations are predictive of sudden cardiac death in patients with chronic heart failure and provide complementary information to NT-proBNP levels | | constitutional
|
|
| --over
|
| |
IL33 and IL1RL1 positive cells were also significantly increased in Alzheimer disease (AD) brains when compared to non-AD brains | |
| Susceptibility
|
to atopic dermatitis to mild preeclampsia |
| Variant & Polymorphism
SNP
| -26999A allele increase the risk of atopic dermatitis |
|
significantly increased mild preeclampsia risk was observed associated with GG genotype of rs1420103 polymorphisms |
| 
|
| Candidate gene
| serum levels of the soluble form serve as a biomarker for ventricular biomechanical strain and provide prognostic information in patients who have symptomatic heart failure (Kakkar 2009) |
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cardiovascular | | | |
| IL33/IL1RL1 not only represents a promising cardiovascular biomarker but also a novel mechanism of intramyocardial fibroblast-cardiomyocyte communication that may prove to be a therapeutic target for the prevention of heart failure | | immunology | inflammatory | | |
| blockade of IL1RL1 is a novel therapeutic strategy for familial hemophagocytic lymphohistiocytosis (FHL) |
| | |
|
| Il1rl1 deletion increases inflammatory bone loss in experimental periapical lesions in mice |